| Project Title | Concomitancy and Indications for Idelalisib Use |
| Date Posted | Tuesday, March 13, 2018 |
| Project ID | cder_mpl1r_wp023 |
| Status | Complete |
| Deliverables | |
| Description | This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016. |
| Medical Product | bendamustine bortezomib chlorambucil cyclophosphamide doxorubicin ibritumomab ibrutinib idelalisib lenalidomide obinutuzumab ofatumumab prednisone rituximab vincristine |
| Population / Cohort | Individuals 18 years of age or older |
| Time Period | July 23, 2014 - December 31, 2015 |
| Assessment Type | Exploratory Analyses |
| Study Type | Modular Program |
| Data Sources | Sentinel Distributed Database (SDD) |
| FDA Center | CDER |
